JP2016532655A5 - - Google Patents

Download PDF

Info

Publication number
JP2016532655A5
JP2016532655A5 JP2016521328A JP2016521328A JP2016532655A5 JP 2016532655 A5 JP2016532655 A5 JP 2016532655A5 JP 2016521328 A JP2016521328 A JP 2016521328A JP 2016521328 A JP2016521328 A JP 2016521328A JP 2016532655 A5 JP2016532655 A5 JP 2016532655A5
Authority
JP
Japan
Prior art keywords
controlled release
levodopa
oral solid
solid formulation
release oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016521328A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016532655A (ja
JP6506271B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/059554 external-priority patent/WO2015054302A1/en
Publication of JP2016532655A publication Critical patent/JP2016532655A/ja
Publication of JP2016532655A5 publication Critical patent/JP2016532655A5/ja
Priority to JP2019059915A priority Critical patent/JP6898375B2/ja
Application granted granted Critical
Publication of JP6506271B2 publication Critical patent/JP6506271B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016521328A 2013-10-07 2014-10-07 レボドパ及び／又はレボドパのエステルの粘膜付着性制御放出配合物、並びにその使用 Active JP6506271B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019059915A JP6898375B2 (ja) 2013-10-07 2019-03-27 レボドパ及び／又はレボドパのエステルの粘膜付着性制御放出配合物、並びにその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361887762P 2013-10-07 2013-10-07
US61/887,762 2013-10-07
PCT/US2014/059554 WO2015054302A1 (en) 2013-10-07 2014-10-07 Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019059915A Division JP6898375B2 (ja) 2013-10-07 2019-03-27 レボドパ及び／又はレボドパのエステルの粘膜付着性制御放出配合物、並びにその使用

Publications (3)

Publication Number Publication Date
JP2016532655A JP2016532655A (ja) 2016-10-20
JP2016532655A5 true JP2016532655A5 (https=) 2017-11-16
JP6506271B2 JP6506271B2 (ja) 2019-04-24

Family

ID=52813592

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016521328A Active JP6506271B2 (ja) 2013-10-07 2014-10-07 レボドパ及び／又はレボドパのエステルの粘膜付着性制御放出配合物、並びにその使用
JP2019059915A Active JP6898375B2 (ja) 2013-10-07 2019-03-27 レボドパ及び／又はレボドパのエステルの粘膜付着性制御放出配合物、並びにその使用
JP2021096298A Pending JP2021127349A (ja) 2013-10-07 2021-06-09 レボドパ及び／又はレボドパのエステルの粘膜付着性制御放出配合物、並びにその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019059915A Active JP6898375B2 (ja) 2013-10-07 2019-03-27 レボドパ及び／又はレボドパのエステルの粘膜付着性制御放出配合物、並びにその使用
JP2021096298A Pending JP2021127349A (ja) 2013-10-07 2021-06-09 レボドパ及び／又はレボドパのエステルの粘膜付着性制御放出配合物、並びにその使用

Country Status (12)

Country Link
US (4) US10098845B2 (https=)
EP (2) EP3054929B1 (https=)
JP (3) JP6506271B2 (https=)
KR (2) KR102266091B1 (https=)
CN (1) CN105658211A (https=)
AU (3) AU2014332024B2 (https=)
CA (1) CA2926082C (https=)
ES (1) ES2823000T3 (https=)
IL (2) IL244920B (https=)
MX (2) MX393588B (https=)
PL (1) PL3054929T3 (https=)
WO (1) WO2015054302A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8377474B2 (en) 2007-12-28 2013-02-19 Impax Laboratories, Inc. Controlled release formulations of levodopa and uses thereof
AU2014332024B2 (en) 2013-10-07 2019-09-26 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US11229600B2 (en) * 2014-09-24 2022-01-25 Vital Beverages Global Inc. Compositions and methods for selective GI tract delivery
CA2902911C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US11759417B2 (en) 2018-02-28 2023-09-19 Shanghai Wd Pharmaceutical Co., Ltd Pharmaceutical composition and preparation method therefor and use thereof
EP3797818B1 (en) * 2018-05-23 2023-01-18 Shanghai WD Pharmaceutical Co., Ltd Controlled-release system of active pharmaceutical ingredient and preparation method therefor
US11911513B2 (en) 2018-05-23 2024-02-27 Shanghai Wd Pharmaceutical Co., Ltd Controlled-release system of active pharmaceutical ingredient and preparation method therefor
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
CN110075345B (zh) * 2019-04-01 2021-12-10 杭州英健生物科技有限公司 适用于胃窥镜喷涂到胃损伤黏膜表面的双组分自粘性胃黏膜保护胶及其应用
US12161755B2 (en) 2020-11-14 2024-12-10 Regents Of The University Of Minnesota Sustained release device for treatment of Parkinson's disease and other disorders
CN116887866A (zh) 2020-12-03 2023-10-13 巴特尔纪念研究院 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
EP4267113A4 (en) * 2020-12-22 2025-02-12 Amneal Pharmaceuticals LLC LEVODOPA DOSING SCHEME
CN114762684B (zh) * 2021-01-14 2023-11-21 华益泰康药业股份有限公司 一种治疗帕金森的缓释胶囊及其制备方法
WO2022216977A1 (en) 2021-04-07 2022-10-13 Batelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
JPWO2024024865A1 (https=) * 2022-07-28 2024-02-01
CN117919217A (zh) * 2022-10-14 2024-04-26 浙江华海药业股份有限公司 一种用于治疗帕金森病的药物组合物及其制备方法
KR102903389B1 (ko) * 2022-11-30 2025-12-23 주식회사한국파마 신경퇴행성 질환 예방 또는 치료용 필름코팅정제
US11931224B1 (en) * 2022-12-19 2024-03-19 Robert Parker Tooth pod
CN116808001A (zh) * 2023-05-04 2023-09-29 上海信谊万象药业股份有限公司 一种多巴丝肼肠溶微丸胶囊及其制备工艺
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
US12441996B2 (en) 2023-12-08 2025-10-14 Battelle Memorial Institute Use of DNA origami nanostructures for molecular information based data storage systems

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3891696A (en) 1973-11-02 1975-06-24 Interx Research Corp Novel, transient pro-drug forms of l-dopa
DE2513940A1 (de) 1975-03-29 1976-10-14 Merck Patent Gmbh Pharmazeutische zubereitung
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
FR2470599A1 (fr) 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
DE3000979A1 (de) 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
DE3124090A1 (de) 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale dipyridamolformen
DE3126703A1 (de) 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
US4424235A (en) 1981-09-14 1984-01-03 Hoffmann-La Roche Inc. Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
US5188840A (en) 1985-09-26 1993-02-23 Chugai Seiyaku Kabushiki Kaisha Slow-release pharmaceutical agent
IT1188212B (it) 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
US4849227A (en) 1986-03-21 1989-07-18 Eurasiam Laboratories, Inc. Pharmaceutical compositions
ES2042520T3 (es) 1986-06-10 1993-12-16 Chiesi Farma Spa Composiciones farmaceuticas que contienen el ester metilico de levodopa, preparacion y aplicaciones terapeuticas del mismo.
NZ220599A (en) 1986-06-16 1990-10-26 Merck & Co Inc Controlled release oral dosage formulation of carbidopa and levodopa
ZA889189B (en) 1986-06-16 1989-08-30 Merck & Co Inc Controlled release combination of carbidopa/levodopa
US4832957A (en) 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
YU213587A (en) 1986-11-28 1989-06-30 Orion Yhtymae Oy Process for obtaining new pharmacologic active cateholic derivatives
FI864875A0 (fi) 1986-11-28 1986-11-28 Orion Yhtymae Oy Nya farmakologiskt aktiva foereningar, dessa innehaollande kompositioner samt foerfarande och mellanprodukter foer anvaendning vid framstaellning av dessa.
US5283352A (en) 1986-11-28 1994-02-01 Orion-Yhtyma Oy Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same
US4855326A (en) 1987-04-20 1989-08-08 Fuisz Pharmaceutical Ltd. Rapidly dissoluble medicinal dosage unit and method of manufacture
JP2782691B2 (ja) 1987-09-29 1998-08-06 ワーナー−ランバート・コンパニー 腸溶製剤の安定化
US4938968A (en) 1988-07-26 1990-07-03 Norjec Development Associates, Inc. Controlled release indomethacin
IT1229856B (it) 1989-04-20 1991-09-13 Recordati Chem Pharm Compresse a rilascio controllato contenenti flavossato.
GB2238047B (en) 1989-11-03 1993-02-10 Orion Yhtymae Oy Stable polymorphic form of (e)-n,n-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide and the process for its preparation
IE66933B1 (en) 1990-01-15 1996-02-07 Elan Corp Plc Controlled absorption naproxen formulation for once-daily administration
US5624960A (en) 1991-01-23 1997-04-29 Isis Pharma Gmbh Orally administrable drugs for the treatment of central dopamine deficiency conditions
DE4101873C2 (de) 1991-01-23 1993-12-09 Isis Pharma Gmbh Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
US5388857A (en) 1992-08-27 1995-02-14 Badger Equipment Company Operator controlled vehicle stabilizer
IT1255522B (it) 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
GB9309749D0 (en) 1993-05-12 1993-06-23 Boots Co Plc Therapeutic agents
IT1264517B1 (it) 1993-05-31 1996-09-24 Ekita Investments Nv Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati
IT1264696B1 (it) 1993-07-09 1996-10-04 Applied Pharma Res Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata
EP0711166A1 (en) 1993-07-22 1996-05-15 Warner-Lambert Company Controlled release tacrine drug delivery systems and methods for preparing same
IT1266565B1 (it) 1993-07-22 1997-01-09 Ct Lab Farm Srl Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico.
US6183778B1 (en) 1993-09-21 2001-02-06 Jagotec Ag Pharmaceutical tablet capable of liberating one or more drugs at different release rates
SG80553A1 (en) 1995-07-20 2001-05-22 Tanabe Seiyaku Co Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract
US5840756A (en) 1995-07-21 1998-11-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition of L-DOPA ester
AUPN605795A0 (en) 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
IT1282576B1 (it) 1996-02-06 1998-03-31 Jagotec Ag Compressa farmaceutica atta a cedere la sostanza attiva in tempi successivi e predeterminabili
IT1282650B1 (it) 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
US5773031A (en) 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
IT1289160B1 (it) 1997-01-08 1998-09-29 Jagotec Ag Compressa farmaceutica completamente rivestita per il rilascio controllato di principi attivi che presentano problemi di
US6756056B2 (en) 1997-04-08 2004-06-29 Alan A. Rubin Treatment of Parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
IT1293764B1 (it) 1997-07-23 1999-03-10 Chiesi Farma Spa Composizioni farmaceutiche sotto forma di compresse effervescenti contenenti un principio attivo instabile in presenza di acqua
IT1295271B1 (it) * 1997-10-03 1999-05-04 Chiesi Farma Spa Monolita contenente uno o piu'farmaci costituito da tre strati a meccanismo di rilascio differenziato
US6372254B1 (en) 1998-04-02 2002-04-16 Impax Pharmaceuticals Inc. Press coated, pulsatile drug delivery system suitable for oral administration
US5945424A (en) 1998-07-31 1999-08-31 G & H Associates, Inc. Treatment of periodic limb movement syndrome
WO2000015197A1 (en) 1998-09-14 2000-03-23 Rubin Alan A Improvement in treatment of parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa
US6602521B1 (en) 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
EP1126826B3 (en) 1998-11-02 2019-05-15 Alkermes Pharma Ireland Limited Multiparticulate modified release composition of methylphenidate
CA2350304A1 (en) 1998-11-10 2000-05-18 Teva Pharmaceutical Industries, Ltd. Dispersible compositions containing l-dopa ethyl ester
WO2000035419A2 (en) 1998-12-17 2000-06-22 Alza Corporation Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
NZ518309A (en) 1999-11-11 2003-05-30 Pharmacia Ab Controlled release tolterodine formulation that releases not less than 80% of the active compound in under 18 hours
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6372252B1 (en) 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
JP2004501190A (ja) 2000-06-23 2004-01-15 テバ　ファーマシューティカル　インダストリーズ　リミティド 治療薬の胃部保留および制御された放出のための急速膨張する組成物とその組成物を含む剤形
US6733781B2 (en) 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
US6531153B2 (en) 2001-05-29 2003-03-11 Drugtech Corporation Composition with sustained release of levodopa and carbidopa
US20040028613A1 (en) 2001-06-25 2004-02-12 Nastech Pharmaceutical Company Inc Dopamine agonist formulations for enhanced central nervous system delivery
IL159812A0 (en) * 2001-07-12 2004-06-20 Teva Pharma Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester in a controlled release core
IL159813A0 (en) 2001-07-12 2004-06-20 Teva Pharma Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core
US6723348B2 (en) 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
US6811794B2 (en) 2001-12-20 2004-11-02 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US7094427B2 (en) 2002-05-29 2006-08-22 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20040166159A1 (en) 2002-05-29 2004-08-26 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa
US20030224045A1 (en) 2002-05-29 2003-12-04 Chien-Hsuan Han Combination immediate release sustained release levodopa/carbidopa dosage forms
US20050147670A1 (en) 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms
US20060013875A1 (en) 2002-05-29 2006-01-19 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
CA2514879C (en) 2003-01-03 2014-09-16 Shire Laboratories Inc. Two or more enteric materials to regulate drug release
CA2520660C (en) 2003-03-28 2013-08-20 Sigmoid Biotechnologies Limited Solid oral dosage form containing seamless microcapsules
ATE341857T1 (de) * 2003-06-04 2006-10-15 Koninkl Philips Electronics Nv Bitdetektionsanordnung und vorrichtung zur wiedergabe von informationen
US20050070608A1 (en) 2003-08-29 2005-03-31 Julius Remenar Pharmaceutical compositions and method of using levodopa and carbidopa
US8815950B2 (en) 2003-08-29 2014-08-26 Janssen Biotech, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
US8007827B2 (en) 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
WO2005099678A1 (en) 2004-04-06 2005-10-27 Transform Pharmaceuticals, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
US8015148B2 (en) 2004-06-30 2011-09-06 International Business Machines Corporation Selective profiler for use with transaction processing applications
JP2006018748A (ja) * 2004-07-05 2006-01-19 Canon Inc 情報処理装置及びその制御方法、並びにコンピュータプログラム及びコンピュータ可読記憶媒体
US20060045865A1 (en) * 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
JP2008516893A (ja) 2004-08-27 2008-05-22 スフェリックス，インク． 多層錠剤および生体接着性剤形
US20070082048A1 (en) * 2005-06-08 2007-04-12 Ronald Warner Sleep aid formulations
WO2007002518A1 (en) 2005-06-23 2007-01-04 Spherics, Inc. Delayed release or extended-delayed release dosage forms of pramipexole
AU2006261893A1 (en) 2005-06-23 2007-01-04 Combinatorx, Incorporated Improved dosage forms for movement disorder treatment
US20070275060A1 (en) 2005-08-05 2007-11-29 Osmotica Costa Rica Sociedad Anonima Extended release solid pharmaceutical composition containing carbidopa and levodopa
KR20080037732A (ko) 2005-08-22 2008-04-30 노파르티스 아게 ｐＨ-의존성 약물, ｐＨ 개질제 및 지연제를 포함하는제약학적 조성물
FR2891459B1 (fr) 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
RU2428176C2 (ru) 2006-01-27 2011-09-10 Юранд, Инк. Системы доставки лекарственного средства, содержащие слабоосновные лекарственные средства и органические кислоты
CN103211779B (zh) 2006-01-27 2016-03-16 阿代尔制药股份有限公司 包含弱碱性选择性5-羟色胺5-ht3阻断剂和有机酸的药物递送系统
US8637080B2 (en) * 2007-06-28 2014-01-28 Osmotica Kereskedelmi és Szolgáltató, KFT Rupturing controlled release device comprising a subcoat
US8377474B2 (en) * 2007-12-28 2013-02-19 Impax Laboratories, Inc. Controlled release formulations of levodopa and uses thereof
AU2009240793B2 (en) * 2008-04-24 2014-07-10 Indice Pty Ltd Power control
US20100331244A1 (en) 2009-06-01 2010-12-30 The University Of Tokyo Pharmaceutical composition, food or drink, and methods related thereto
WO2011056240A2 (en) * 2009-11-09 2011-05-12 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
US20140037614A1 (en) 2011-04-05 2014-02-06 Knut Pettersson Therapeutic and prophylactic methods, uses and compositions comprising anexin a5
EP2508174A1 (en) * 2011-04-06 2012-10-10 Ljiljana Sovic Brkicic Pharmaceutical composition
US20130195973A1 (en) 2012-01-30 2013-08-01 Ranbaxy Laboratories Limited Extended release pharmaceutical dosage forms of carbidopa and levodopa and process of preparation thereof
AU2014332024B2 (en) * 2013-10-07 2019-09-26 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof

Similar Documents

Publication Publication Date Title
JP2016532655A5 (https=)
JP6506271B2 (ja) レボドパ及び／又はレボドパのエステルの粘膜付着性制御放出配合物、並びにその使用
EA201390981A1 (ru) Разрушающаяся во рту таблетка
RU2015110825A (ru) Устойчивая к действию желудочного сока фармацевтическая или нутрицевтическая композиция со стойкостью к влиянию этанола
HRP20221269T1 (hr) Pripravci za liječenje mijelofibroze
NZ594648A (en) Sustained release oral dosage forms of an r-baclofen prodrug
HRP20120633T1 (hr) Formulacija rasagilina s odgođenim oslobađanjem
RU2011135417A (ru) Галеновы препараты органических соединений
JP2008520736A5 (https=)
RU2015128794A (ru) Композиция перорально распадающейся таблетки, обеспечивающая повышенную биодоступность
RU2012142811A (ru) Фармацевтические композиции и пероральные дозированные формы пролекарства леводопы и способы применения
AU2014332024A1 (en) Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
NZ586025A (en) Rasagiline mesylate tablet coated with a composisiton comprising methacrylic acid - ethyl acrylate copolymer and triethyl citrate
JP2017532363A5 (https=)
JP2020510000A5 (https=)
JP2019506401A5 (https=)
SI2760821T1 (en) A salt salt of an anti-inflammatory substituted cyclobutenedione compound
MX356579B (es) Composicion farmaceutica o nutraceutica de resistencia gastrica con resistencia contra la influenza de etanol.
JP2013502446A5 (https=)
MY165003A (en) Compositions of rotigotine, derivatives thereof, or pharmaceutically acceptable salts of rotigotine or its derivative
JP2005528430A5 (https=)
MX2015010449A (es) Composicion farmaceutica multiparticulada que comprende una multitud de dos clases de granulos.
JP2008522989A5 (https=)
RU2015140572A (ru) Способы лечения колоректального рака
RU2018111690A (ru) Пероральная лекарственная форма будесонида